Last reviewed · How we verify
anti-CGRP monoclonal antibodies
At a glance
| Generic name | anti-CGRP monoclonal antibodies |
|---|---|
| Sponsor | IRCCS San Raffaele Roma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications (PHASE4)
- Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies
- i-NEED: NEw migrainE Drugs Database
- EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
- CGRP Inhibition, Autonomic Function, and Migraine
- Transcranial Direct Current Stimulation Plus Monoclonal Antibodies Acting on the CGRP Pathway for Migraine (NA)
- "Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment"
- Biochemical Profiling of Migraine Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-CGRP monoclonal antibodies CI brief — competitive landscape report
- anti-CGRP monoclonal antibodies updates RSS · CI watch RSS
- IRCCS San Raffaele Roma portfolio CI